Literature DB >> 34337438

Molecular imaging for systemic sclerosis-interstitial lung disease.

Elizabeth R Volkmann1.   

Abstract

Entities:  

Year:  2021        PMID： 34337438      PMCID： PMC8323663          DOI： 10.1016/s2665-9913(21)00004-7

Source DB:  PubMed          Journal:  Lancet Rheumatol        ISSN： 2665-9913


× No keyword cloud information.
  6 in total

1.  Cyclophosphamide versus placebo in scleroderma lung disease.

Authors:  Donald P Tashkin; Robert Elashoff; Philip J Clements; Jonathan Goldin; Michael D Roth; Daniel E Furst; Edgar Arriola; Richard Silver; Charlie Strange; Marcy Bolster; James R Seibold; David J Riley; Vivien M Hsu; John Varga; Dean E Schraufnagel; Arthur Theodore; Robert Simms; Robert Wise; Fredrick Wigley; Barbara White; Virginia Steen; Charles Read; Maureen Mayes; Ed Parsley; Kamal Mubarak; M Kari Connolly; Jeffrey Golden; Mitchell Olman; Barri Fessler; Naomi Rothfield; Mark Metersky
Journal:  N Engl J Med       Date:  2006-06-22       Impact factor: 91.245

2.  Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.

Authors:  Donald P Tashkin; Elizabeth R Volkmann; Chi-Hong Tseng; Hyun J Kim; Jonathan Goldin; Philip Clements; Daniel Furst; Dinesh Khanna; Eric Kleerup; Michael D Roth; Robert Elashoff
Journal:  Ann Rheum Dis       Date:  2014-12-01       Impact factor: 19.103

3.  Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease.

Authors:  Grace Hyun J Kim; Donald P Tashkin; Pechin Lo; Matthew S Brown; Elizabeth R Volkmann; David W Gjertson; Dinesh Khanna; Robert M Elashoff; Chi-Hong Tseng; Michael D Roth; Jonathan G Goldin
Journal:  Arthritis Rheumatol       Date:  2019-12-26       Impact factor: 10.995

4.  Severe restrictive lung disease in systemic sclerosis.

Authors:  V D Steen; C Conte; G R Owens; T A Medsger
Journal:  Arthritis Rheum       Date:  1994-09

5.  Natural History of Systemic Sclerosis-Related Interstitial Lung Disease: How to Identify a Progressive Fibrosing Phenotype.

Authors:  Elizabeth R Volkmann
Journal:  J Scleroderma Relat Disord       Date:  2019-12-05

6.  Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Authors:  Donald P Tashkin; Michael D Roth; Philip J Clements; Daniel E Furst; Dinesh Khanna; Eric C Kleerup; Jonathan Goldin; Edgar Arriola; Elizabeth R Volkmann; Suzanne Kafaja; Richard Silver; Virginia Steen; Charlie Strange; Robert Wise; Fredrick Wigley; Maureen Mayes; David J Riley; Sabiha Hussain; Shervin Assassi; Vivien M Hsu; Bela Patel; Kristine Phillips; Fernando Martinez; Jeffrey Golden; M Kari Connolly; John Varga; Jane Dematte; Monique E Hinchcliff; Aryeh Fischer; Jeffrey Swigris; Richard Meehan; Arthur Theodore; Robert Simms; Suncica Volkov; Dean E Schraufnagel; Mary Beth Scholand; Tracy Frech; Jerry A Molitor; Kristin Highland; Charles A Read; Marvin J Fritzler; Grace Hyun J Kim; Chi-Hong Tseng; Robert M Elashoff
Journal:  Lancet Respir Med       Date:  2016-07-25       Impact factor: 30.700
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.